| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b40569c7c79680bf9ecee2955a2f936
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebbf62aa8d5562924a3c5dc5c18fe3e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87d254ce21620aadb777b298cba29847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d549b9a65c30df0204aa91791d65251c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75ea90f788c815263ba50e88e0507615 |
| publicationDate |
2017-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201741339-A |
| titleOfInvention |
Administration of bispecific constructs that bind to CD33 and CD3 for use in the treatment of myeloid leukemia |
| abstract |
The present invention provides a bispecific construct comprising a first binding domain that specifically binds to CD33 and a second binding domain that specifically binds to CD3 for use in a method of treating myeloid leukemia, wherein the construct is administered The construction period is not applied for a period of up to 14 days, and then for at least 14 days. Furthermore, the invention provides a method for treating myeloid leukemia comprising administering a therapeutically effective amount of the bispecific construct; and the use of the bispecific construct for the preparation of a bone marrow-like leukemia Pharmaceutical composition. |
| priorityDate |
2016-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |